Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant stock price increase of nearly 900% since early June, with a current price of 1.3 HKD and a trading volume of 15.1764 million HKD, following the approval of its innovative drug for Gaucher disease treatment [1][1][1] Company Summary - On May 15, the National Medical Products Administration approved Beihai Kangcheng's application for the injectable Velaglucerase beta (brand name: Gorening) for long-term enzyme replacement therapy in adolescents and adults aged 12 and above with Type I and III Gaucher disease [1][1][1] - On July 3, Beihai Kangcheng announced that the first prescription for Gorening had been issued, with the first patient receiving treatment at Xinhua Hospital [1][1][1] Industry Summary - The launch of Velaglucerase beta is expected to create a competitive landscape in the domestic Gaucher disease treatment market, with both imported and domestic drugs vying for market share [1][1][1] - Although other companies are also focusing on Gaucher disease treatment drug development, their progress is relatively slow, which may allow Velaglucerase beta to establish a strong foothold in the domestic market due to its domestic and first-mover advantages [1][1][1] - The market accessibility for Gaucher disease treatment is anticipated to improve significantly, and there is potential for future global expansion, indicating possible significant business development opportunities [1][1][1]

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant stock price increase of over 25%, with a cumulative rise of nearly 900% since early June, indicating strong market interest and potential growth in the biopharmaceutical sector [1] Group 1: Company Developments - On May 15, the National Medical Products Administration approved the injection of Velaglucerase beta (brand name: Gorening) for long-term enzyme replacement therapy in patients aged 12 and above with Type I and III Gaucher disease [1] - As of July 3, Beihai Kangcheng reported that the first prescription for Gorening has been issued, with the first patient receiving treatment at Xinhua Hospital [1] Group 2: Market Implications - The launch of Velaglucerase beta is expected to create a competitive landscape in the domestic Gaucher disease treatment market, with both imported and domestic drugs vying for market share [1] - Although other companies are also focusing on Gaucher disease treatment drug development, their progress is relatively slow, suggesting that Velaglucerase beta may leverage its domestic and first-mover advantages to establish a strong foothold in the market [1] - There is potential for significant market accessibility improvements and future opportunities for global expansion in the Gaucher disease treatment sector, indicating possible major business development (BD) prospects [1]